COVID-19 prophylaxis (excluding children) meta-analysis

• suggested 91 % decrease in 6 months symptomatic COVID with a moderate degree of certainty due to some concern in risk of bias
• suggested 82 % decrease in confirmed Covid-19, from 1st dose with a moderate degree of certainty due to some concern in risk of bias
• suggested 82 % decrease in vaccine efficacy from randomization (ITT) with a moderate degree of certainty due to some concern in risk of bias
• demonstrated 95 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 3.9-fold increase in related AE (TRAE) with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 1.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 74 % increase in severe adverse events with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 9.7-fold increase in lymphadenopathy, any with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 2.7-fold increase in musculoskeletal and connective tissue disorders, any with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 23.9-fold increase in local adverse reaction, any, dose 1 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 22.0-fold increase in local adverse reaction, any, dose 2 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 63 % increase in systemic adverse reaction, any, dose 1 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 3.6-fold increase in systemic adverse reaction, any, dose 2 with a moderate degree of certainty due to some concern in risk of bias

• suggested 95 % decrease in confirmed Covid-19, from 1st dose with a moderate degree of certainty due to some concern in risk of bias
• suggested 93 % decrease in vaccine efficacy from randomization (ITT) with a moderate degree of certainty due to some concern in risk of bias
• demonstrated 94 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
• demonstrated 98 % decrease in severe COVID-19 occurrence (PE) with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 14 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 17.4-fold increase in arthralgia, grade 3-4 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 41 % increase in hypersensitivity, all terms with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 2.5-fold increase in lymphadenopathy, grade 3-4 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 26.6-fold increase in myalgia, grade 3-4 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 42.3-fold increase in fever, grade 3-4 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 32.7-fold increase in local adverse reaction, any, dose 2 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 14.0-fold increase in local adverse reaction, grade 3-4, dose 2 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 5.7-fold increase in systemic adverse reaction, any, dose 2 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 8.5-fold increase in systemic adverse reaction, grade 3-4, dose 2 with a moderate degree of certainty due to some concern in risk of bias

• suggested 87 % decrease in hospitalization
• suggested 94 % decrease in symptomatic Covid-19

• suggested 90 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias

• suggested 81 % decrease in hospitalization
• suggested 52 % decrease in symptomatic Covid-19,confirmed COVID (any severity)

• suggested 59 % decrease in death D28
• statistically significant 2.9-fold increase in myocarditis

• statistically significant 24 % increase in intracranial hemorrhage

• statistically significant 22 % increase in paresthesia

• suggested 17 % decrease in symptomatic Covid-19

• suggested 97 % decrease in symptomatic Covid-19

• statistically significant 43 % increase in herpes zoster infection but with a very low degree of certainty due to critical risk of bias
• statistically significant 2.2-fold increase in myocarditis but with a very low degree of certainty due to critical risk of bias
• statistically significant 40 % increase in appendicitis but with a very low degree of certainty due to critical risk of bias
• statistically significant 1.4-fold increase in lymphadenopathy, any but with a very low degree of certainty due to critical risk of bias

• suggested 61 % decrease in confirmed COVID (any severity)

• suggested 86 % decrease in infection (PCR positive symptomatic or not),confirmed COVID (any severity)

• suggested 94 % decrease in deaths
• suggested 94 % decrease in hospitalization

• suggested 97 % decrease in deaths
• suggested 97 % decrease in hospitalization
• suggested 97 % decrease in symptomatic Covid-19

• suggested 89 % decrease in infection (PCR positive symptomatic or not),confirmed COVID (any severity)

• suggested 81 % decrease in hospitalization,severe COVID-19 occurrence but with a low degree of certainty due to high risk of bias
• suggested 76 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias

• suggested 75 % decrease in hospitalization,severe COVID-19 occurrence but with a low degree of certainty due to high risk of bias
• suggested 42 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias

• suggested 51 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias

• suggested 52 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias

• statistically significant 36 % increase in Bell's palsy

• statistically significant 36 % increase in Bell's palsy

• suggested 73 % decrease in confirmed COVID (any severity)
• suggested 91 % decrease in confirmed COVID (any severity)
• suggested 90 % decrease in hospitalization

• suggested 44 % decrease in death or ventilation
• suggested 46 % decrease in death or ventilation
• suggested 76 % decrease in death or ventilation
• suggested 85 % decrease in hospitalization
• suggested 85 % decrease in hospitalization
• suggested 65 % decrease in hospitalization

• suggested 95 % decrease in confirmed COVID (any severity)

• suggested 30 % decrease in confirmed COVID (any severity)

• suggested 82 % decrease in confirmed COVID (any severity)

• suggested 94 % decrease in symptomatic Covid-19

• suggested 91 % decrease in symptomatic Covid-19

• suggested 91 % decrease in symptomatic Covid-19

• suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)

• suggested 85 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias

• suggested 53 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias

• suggested 70 % decrease in hospitalization
• suggested 50 % decrease in symptomatic Covid-19,confirmed COVID (any severity)

• suggested 84 % decrease in hospitalization,severe COVID-19 occurrence but with a low degree of certainty due to high risk of bias

• statistically significant 1.4-fold increase in Bell's palsy but with a very low degree of certainty due to critical risk of bias